News 2023-03-25
Porton Released 2022 CSR Report
Porton Pharma Solutions Ltd. recently released 2022 CSR Report which is its seventh CSR report since IPO. This report demonstrates the company's ideas and achievements in fulfilling social responsibility from aspects such as "improving corporate governance", "providing high-quality services", "empowering employee development", "practicing green development", and "participating in community co-development".
Portonisalways committed to sustainable development，adopting a development model that balances economic benefits with gover-nance, environment,and social welfare, in order tocontinuously enhance the company'sriskresistanceandsustainable business capabilities.
Currency:RMB
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
